Vascular dysfunction in diabetes mellitus

Lancet

Volumn 350, Issue SUPPL.1, 1997, Pages 9-13

  Feener, Edward P ^a   King, George L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INSULIN; SORBITOL;

BASEMENT MEMBRANE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; HYPERGLYCEMIA; MICROVASCULATURE; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

EID: 0030871260     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(97)90022-2     Document Type: Article

References (35)

1. Zhu D, Kim Y, Steffes MW, et al. Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry. Kidney Int 1994; 45: 425-33.
2. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-30.
3. Monnier VM, Glomb M, Elgawish A, Sell DR. The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 1996; 45 (suppl 3): S67-S72.
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-87.
5. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. JAMA 1990; 263: 2893-98.
6. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217-25.
7. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118: 344-49.
8. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated initmal hyperplasia. Circulation 1997; 95: 1366-69.
9. Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-100.
10. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996; 93: 1073-78.
11. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996; 47: 315-31.
12. Bell DSH. Diabetic cardiomyopathy. Diabetes Care 1995; 18: 708-14.
13. Nishio Y, Warren CE, Buczek-Thomas JA, et al. Identification and characterization of a gene regulating enzymatic glycosylation which is induced by diabetes and hyperglycemia specifically in rat cardiac tissue. J Clin Invest 1995; 96: 1759-67.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
15. Brownlee M. Lilly Lecture 1993. Diabetes 1994; 43: 836-41.
16. Tilton RG, Chang K, Hasan KS, et al. Prevention of diabetic vascular dysfunction by guanidines. Diabetes 1993; 42: 221-32.
17. Sorbinil Retinopathy Trial Research Group. The sorbinil retinopathy trial: neuropathy results. Neurology 1993; 43: 1141-49.
18. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-63.
19. Koya D, Jirousek MR, Lin Y-W, et al. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J Clin Invest (in press)
20. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-31.
21. Wells-Knecht MC, Thorpe SR, Baynes JW. Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 1995; 34: 15134-41.
22. Koya D, Lee IK, Ishii H, Kanoh H, King GL. Prevention of glomerular dysfunction in diabetic rats by treatment with d-α-tocopherol. J Am Soc Nephrol 1997; 8: 526-35.
23. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-57.
24. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. Circulation 1996; 93: 1809-17.
25. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-15.
26. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. J Clin Invest 1996; 98: 894-98.
27. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 1996; 97: 2601-10.
28. Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 22-28.
29. Kroder G, Bossenmaier B, Kellerer M, et al. Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. J Clin Invest 1996; 97: 1471-77.
30. Velloso LA, Folli F, Sun XJ, White MF, Saad MJA, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996; 93: 12490-95.
31. Jiang ZY, Lin Y-W, Clermont AC, Igarashi M, King GL. Direct demonstration of selective insulin resistance on PI 3-kinase pathway in vascular tissues in obese Zucker (fa/fa) rats. Diabetes 1997; 46 (suppl): 210 (abstr).
32. Feener EP, Hansen H, Folli F. Angiotensin II inhibits insulin signaling in rat aortic smooth muscle cells. Diabetes 1997; 46 (suppl): 212 (abstr).
33. Aiello LP. Implications for novel growth factor therapies in diabetic retinopathy. Curr Opin Endocrinol Diabet 1996; 3: 307-14.
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
35. Garg R,Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-56.